earnings
confidence high
sentiment negative
materiality 0.70
Emmaus Q3 net loss $2.1M; revenue down 38% YoY to $3.4M on generic competition
Emmaus Life Sciences, Inc.
2025-Q3 EPS reported
-$0.09
revenue$8,601,000
- Net loss of $2.1M ($0.03/share) vs net income of $1.8M in Q3 2024.
- Revenue fell 38% to $3.4M from $5.5M; decline driven by generic L-Glutamine in U.S. and lower MENA sales.
- Operating expenses reduced 43% to $2.4M due to workforce reduction and cost cuts.
- Income from operations $0.7M vs $0.8M prior year, partially offsetting revenue drop.
- Cash and equivalents dropped to $0.3M at Sept 30 from $1.4M at Dec 31, 2024.